Additionally, miR-29 exhibits anti-tumor effects outside of angiogenesis, including cell cycle inhibition and apoptosis promotion, and appears to elicit synergistic effects with MYC inhibition and STAT1 activation. The gene discussed is STAT1; the disease is neoplasm.